Process of making an enteral formula containing long-chain polyunsaturated fatty acids
First Claim
1. A process for the production of an infant formula containing egg phospholipids having improved organoleptic properties comprising the steps of:
- (a) forming a 2-15% by weight aqueous dispersion of egg phospholipids;
(b) subjecting said dispersion to de-aeration;
(c) combining said de-aerated dispersion with a mixture of protein, carbohydrates, vitamins and minerals, to form said infant formula; and
(d) homogenizing said infant formula.
1 Assignment
0 Petitions
Accused Products
Abstract
Enteral formulas that contain long-chain polyunsaturated fatty acids (PUFAs) and a process for making such enteral compositions are described. More particularly, the invention relates to enteral compositions which provide long chain PUFAs arachidonic acid (AA) and docosahexaenoic acid (DHA) essentially free of cholesterol and may be derived from egg yolk lipids, and thus are predominantly in a phospholipid form. The process of making such a composition provides improved organoleptic and stability properties. Enteral compositions according to this invention may be used to feed infants, particularly pre-term infants, to promote neural development and development of visual acuity, and to reduce the incidence of necrotizing enterocolitis.
-
Citations
18 Claims
-
1. A process for the production of an infant formula containing egg phospholipids having improved organoleptic properties comprising the steps of:
-
(a) forming a 2-15% by weight aqueous dispersion of egg phospholipids; (b) subjecting said dispersion to de-aeration; (c) combining said de-aerated dispersion with a mixture of protein, carbohydrates, vitamins and minerals, to form said infant formula; and (d) homogenizing said infant formula. - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
-
8. A process for the production of an enteral formula comprising egg phospholipids, said method comprising the steps of:
-
(a) providing egg phosphatide essentially free of cholesterol; (b) dispersing said egg phosphatide at about at least 2 percent by weight in an aqueous phase to form a phospholipid dispersion prior to mixing said phospholipid with any other lipid component; and (c) combining said phospholipid dispersion with slurries of other components of said enteral formula. - View Dependent Claims (9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
-
Specification